Identification of the immunogenic domains in HBsAg preS1 region using overlapping preS1 fragment fusion proteins

World Journal of Gastroenterology

Volumn 11, Issue 14, 2005, Pages 2088-2094

  Hu, Wei Guo ^a   Wei, Jun ^a,b   Xia, Heng Chuan ^a   Yang, Xin Xiu ^a   Li, Feng ^a   Li, Guang Di ^a   Wang, Yuan ^a   Zhang, Zu Chuan ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

GST fusion protein; HBV; Immunogenic domain; Overlapping; preS1

Indexed keywords

ANTIBODY; EPITOPE; FREUND ADJUVANT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HYBRID PROTEIN; PROTEIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; OPEN READING FRAME; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

EID: 17444415751     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i14.2088     Document Type: Article

References (42)

1. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol 1984; 52: 396-402
2. Ganem D, Varmus HE. The molecular biology of hepatitis B virus. Ann Rev Biochem 1987; 56: 651-693
3. Beasley RP, Hwang LY. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 1984; 4: 113-121
4. Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132: 723-731
5. Blumberg BS. Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. Proc Natl Acad Sc USA 1997; 94: 7121-7125
6. Lee CL, Ko Y. C. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 1997; 99: 351-353
7. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin S A, Orenstein W A (Eds), Vaccines. 3rd ed. London Saunders 1999: 158-182
8. West DJ, Calandra GB, Ellis RW. Vaccination of infants and children against hepatitis B. Pediatr Clin North Am 1990; 37 585-601
9. André FE. Overview of a 5-year clinical experience with yeast-derived hepatitis B vaccine. Vaccine 1990; 8: s74-80
10. Milich DR. Genetic and molecular basis for T- and B-cell recognition of hepatitis B viral antigens. Immunol Rev 1987; 99: 71-103
11. Milich DR. T-and B-cell recognition of hepatitis B viral antigens. Immunol Today 1988; 9: 380-386
12. Horsfall AC, Hay FC, Soltys AJ, Jones MG. Epitope mapping. Immunol Today 1991; 12: 211-213
13. Milich DR, McLachlan A, Moriarty A, Thornton GB. A single 10-residue pre-S (1) can prime T cell help for anti-body production to multiple epitopes within the pre-S (1), pre-S (2), and S regions of HBsAg. J Immunol 1987; 138: 4457-4465
14. Park JH, Cho EW, Lee YJ, Shin SY, Kim KL. Determination of the protective effects of neutralizing anti-hepatitis B virus (HBV) immunoglobulins by epitope mapping with recombinant HBV surface-antigen proteins. Microbiol Immunol 2000; 44: 703-710
15. Kuroki K, Floreani M, Mimms LT, Ganem D. Epitope mapping of the preS1 domain of the hepatitis B virus large surface protein. Virology 1990; 176: 620-624
16. Küttner G, Kramer A, Schmidtke G, Giessmann E, Dong L, Roggenbuck D, Scholz C, Seifert M, Stigler RD, Schneider-Mergener J, Porstmann T, Höhne W. Characterization of neutralizing anti-pre-S1 and anti-pre-S2 (HBV) monoclonal antibodies and their fragments. Mol Immunol 1999; 36: 669-683
17. Ryu CJ, Kim YK, Hur H, Kim HS, Oh JM, Kang YJ, Hong HJ. Mouse monoclonal antibodies to hepatitis B virus preS1 produced after immunization with recombinant preS1 peptide. Hybridoma 2000; 19 185-189
18. Maeng CY, Ryu CJ, Gripon P, Guguen-Guillouzo C, Hong HJ. Fine mapping of virus-neutralizing epitopes on hepatitis B virus preS1. Virology 2000; 270: 9-16
19. Pizarro JC, Normand BV, Riottot MM, Budkowska A, Bentley GA. Structural and functional characterization of a monoclonal antibody specific for the preS1 region of hepatitis B virus. FEBS Lett 2001; 509: 463-468
20. Petit MA, Strick N, Dubanchet S, Capel F, Neurath AR. Inhibitory activity of monoclonal antibody F35.25 on the interaction between hepatocytes (HepG2 cells) and preS1-specific ligands. Mol Immunol 1991; 28: 517-521
21. Ferrari C, Cavalli A, Penna A, Valli A, Bertoletti A, Pedretti G, Pilli M, Vitali P, Neri TM, Giuberti T. Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology 1992; 103: 255-263
22. Bertino JS Jr, Tirrell P, Greenberg RN, Keyserling HL, Poland GA, Gump D, Kumer ML, Ramsey K. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, Pre-S1, and Pre-S2 particles for revaccination of healthy adult non-responders. J Inf Dis 1997; 175: 678-681
23. Holzer GW, Mayrhofer J, Leitner J, Blum M, Webersinke G, Heuritsch S, Falkner FG. Overexpression of hepatitis B virus surface antigens including the preS1 region in a serum-free Chinese hamster ovary cell line. Protein Expr Purif 2003; 29: 58-69
24. Kniskern PJ, Hagopian A, Burke P, Dunn N, Emini EA, Miller WJ, Yamazaki S, Ellis RW. A candidate vaccine for hepatitis B containing the complete viral surface protein. Heptatology 1988; 8: 82-87
25. Xu X, Li GD, Kong YY, Yang HL, Zhang ZC, Cao HT, Wang Y. A modified hepatitis B virus surface antigen with the receptor-binding sites for hepatocytes at its C terminus: Expression, antigenicity and immunogenicity. J Gen Virol 1994; 75: 3673-3677
26. Petre J, Rutgers T, Hauser P. Properties of a recombinant yeast-derived hepatitis B surface antigen containing S, preS2 and preS1 antigenic domains. Arch Virol 1992; 4: s137-141
27. Prange R, Werr M, Birkner M, Hilfrich R, Streeck RE. Properties of modified hepatitis B virus surface antigen particles carrying preS epitopes. J Gen Virol 1995; 76: 2131-2140
28. Alberti A, Gerlich WH, Heermann KH, Pontisso P. Nature and display of hepatitis B virus envelop protein and the humoral immune response. Springer Semin Immunopathol 1990; 12: 5-23
29. Hu WG, Li F, Yang XX, Li Z, Xia HC, Li GD, Wang Y, Zhang ZC. A flexible peptide linker enhances the immunoreactivity of two copies HBsAg preS1 (21-47) fusion protein. J Biotechnol 2004; 107: 83-90
30. Wei J, Wang YQ, Lu ZM, Li GD, Wang Y, Zhang ZC. Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay. World J Gastroenterol 2002; 8: 276-281
31. Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986; 46: 429-436
32. Ou JH, Rutter WJ. Regulation of secretion on the hepatitis B virus major surface antigen by the preS-1 protein. J Virol 1987; 61: 782-786
33. Persing DH, Varmus HE, Ganem D. Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. Science 1986; 234: 1388-1391
34. Neurath AR, Kent SB, Strick N, Stark D, Sproul P. Genetic restriction of immune responsiveness to synthetic peptides corresponding to sequences in the pre-S region of the hepatitis B virus (HBV) envelope gene. J Med Virol 1985; 17: 119-125
35. Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB. Immune response to the pre-S (1) region of the hepatitis B surface antigen (HBsAg): A pre-S (1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol 1986; 137: 315-322
36. Jilg W. Novel hepatitis B vaccines. Vaccine 1998; 16: s65-68
37. Alberti A, Cavalletto D, Chemello L, Belussi F, Fattovich G, Pontisso P, Milanesi G, Ruol A. Fine specificity of human antibody response to the preS1 domain of hepatitis B virus. Hepatology 1990; 12: 199-203
38. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988; 67: 31-40
39. Wei J, Liu XJ, Wang YQ, Lu ZM, Li GD, Wang Y, Zhang ZC. Development of the diagnostic immunoassay to detect anti-preS1 (21-47 aa) antibody-a marker suggesting the health improvement of hepatitis B patients. Clin Chim Acta 2002; 317: 159-169
40. Heermann KH, Kruse F, Seifer M, Gerlich WH. Immunogenicity of the gene S and pre-S domains in hepatitis B virions and HBsAg filaments. Intervirology 1987; 28: 14-25
41. Milich DR, Leroux-Roels GG. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003; 2: 248-257
42. Cavalletto D, Pontisso P, Belussi F, Alberti A. Fine specificity of antibodies precipitating Dane particles in hepatitis B. J Hepatol 1988; 7: s19-22